Department of Haematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Br J Haematol. 2020 Apr;189(1):117-121. doi: 10.1111/bjh.16290. Epub 2019 Nov 4.
In this nationwide, population-based study, we assessed trends in primary treatment and survival among 687 patients with nodular lymphocyte-predominant Hodgkin lymphoma (75% males; median age, 40 years; and 74% stage-I/II disease) diagnosed in the Netherlands between 1993-2016. There were no noteworthy changes in the application of primary therapy over time among adult patients across the different disease stages and age groups. Survival among various subgroups of adult patients was largely comparable to the expected survival of the general population. A particularly encouraging finding was that young adult patients experienced virtually no excess mortality, as compared to the general population.
在这项全国性的基于人群的研究中，我们评估了 687 例结节性淋巴细胞为主型霍奇金淋巴瘤患者（75%为男性；中位年龄为 40 岁；74%为Ⅰ/Ⅱ期疾病）的主要治疗和生存趋势，这些患者于 1993 年至 2016 年间在荷兰确诊。不同疾病阶段和年龄组的成年患者中，主要治疗方法随时间的推移并没有明显改变。各成年患者亚组的生存情况与一般人群的预期生存情况基本相当。一个特别令人鼓舞的发现是，与一般人群相比，年轻成年患者的死亡人数实际上没有增加。
